Is the current diagnostic algorithm reliable for selecting cases for EGFR - and KRAS -mutation analysis in lung cancer?

Highlights • EGFR - and KRAS -mutations in lung cancer are relevant for treatment decisions. • Current guidelines do not advise to analyze squamous cell carcinomas. • We examined the fraction of mutations that would have been missed in our database. • 2.0% (2/102) of EGFR - and 1.7% (4/237) of KRAS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-07, Vol.89 (1), p.19-26
Hauptverfasser: Vincenten, Julien P.L, Smit, Egbert F, Grünberg, Katrien, Postmus, Pieter E, Snijders, Peter J.F, Witte, Birgit I, Heideman, Daniëlle A.M, Thunnissen, Erik
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • EGFR - and KRAS -mutations in lung cancer are relevant for treatment decisions. • Current guidelines do not advise to analyze squamous cell carcinomas. • We examined the fraction of mutations that would have been missed in our database. • 2.0% (2/102) of EGFR - and 1.7% (4/237) of KRAS -mutations would not have been tested. • The percentage is slightly higher than the suggested threshold of 1% for EGFR.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.04.005